Immunotherapy is a preferred option for oral cancer patients during COVID-19 pandemic?

Abstract

Table 1 Status and strategies for oral cancer patients during COVID-2019 pandemic.

Toward an understanding of regulatory T cells in COVID‐19: A systematic review

“…Full-text articles were retrieved and reviewed in detail. From 188 references, 154 were reviews, 6 studies did not provide any definition for Treg markers, [39][40][41][42][43][44] one paper did not use appropriate Treg markers, 45 1 study did not present the results of Treg evaluation, 46 4 articles were commentary, [47][48][49][50] and 2 papers were hypothesis. 51,52 Twenty studies were included in the methodological quality assessment.…”

Oral cavity cancer management during the COVID-19 pandemic

“…They concluded that primary radiotherapy and chemoradiotherapy were inferior to surgical management for oral squamous cell carcinoma. Nevertheless, in this special COVID-19 pandemic situation, if there is a lack of medical resources to protect patients from COVID-19 infection, it has been suggested that surgery could be replaced with concurrent chemoradiation therapy, radiation therapy or immunotherapy temporarily to slow disease progression 8 .…”